medigraphic.com
ISSN 1817-5996 (Electronic)

2011, Number 17

<< Back Next >>

Rev Cub de Reu 2011; 13 (17)

Artritis Reumatoide: beneficios clínicos observados en pacientes tratados con anticuerpo monoclonal Itolizumab. (T1h mAB), 2 años después de recibir tratamiento

Prada HDM, Rosabal CNM, Molinero RC, Gómez MJA, Hernández CIM, López MAM, Rodríguez MJM, Méndez RJ, Pereira TJA, Hernández CP, Ávila AY

Language: Spanish
References: 43
Page:
PDF size: 162.06 Kb.


ABSTRACT

No abstract.


REFERENCES

  1. Strand V. Recent advances in the treatment of rheumatoid arthritis. Clin. Cornerstone 1999; 2(2): 38-50

  2. Miller-Blair DL, Robbins DL. rheumatoid arthritis, new science, new treatment. Geriatrics 1993; 48(6) 28-38

  3. Manual SER de las Enfermedades Reumáticas. 2004:169

  4. Guía Práctica Clínica para el manejo de la Artritis Reumatoide en España. 2007.

  5. Pinals RS, Masi AT, Larsen RA. Et al. Preliminary criteria for clinical remission in rheumathoid arthritis. Arthritis Rheum. 1981; 24:1308-1315

  6. Lopez A. Tratamiento de la AR con inductores de remisión. Revista Med Chile v. 136 n.11 Santiago nov.2008: 1468-1475

  7. A Balsa. Terapéutica de la AR. Reumatología clínica, ISSN 1699-258X, Vol. 3, Nº. 1, 2007: 38-44

  8. Prevoo MLL, Van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte BA, van Riel PLCM.. Gunther F. Modified disease activity scores that include twenty-eight-joint. Arthritis Rheum. 1995; 38:44-8.

  9. Boers M, Tugwell P. The validity of pooled outcome measures (indices) in rheumatoid arthritis clinical trials. J Rheumatol 1993; 20:568-74

  10. MeenanRF: The AIMS approach to health status measurements: conceptual background and measurement properties. J Rheumatol 1982; 9: 785-88

  11. Fries JF. Spitz P. Kraines, et al. Assesment of patient outcome in arthritis. Arthritis Rheum 1980; 23:137-45

  12. Enrique Batlle-Gualda. Concepción Chalmeta. Calidad de vida en la artritis reumatoide. Revista Española de Reumatología, Volumen 1, número 1, 2002

  13. Revista Cubana de Reumatología. 2002; IV, (1): 52

  14. Yelin E. Arthritis: The cumulativ impact of a commom chronic condition. Arthritis R Rheum 1992; 35 (5): 498-497

  15. C. Rodríguez Lozano Seguridad de las terapias biológicas: nuevos datos de BIOBADASER. / Reumatol Clin. 2011;6(S3):S1–S6

  16. Comité Científico de BIOBADASER. BIOBADASER: Registro español de acontecimientos adversos de terapias biológicas en enfermedades reumáticas. Rev Esp Reumatol. 2002;29:292–99

  17. Smolen JC. Et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2007, 66: 143—150

  18. Genovese MC. Et al. Abatecept for Rheumatoid Arthritis refractory to TNFalfa inhibition. NEJM, 2005 353:11, 1114—23

  19. Swack JA, Mier JW, Romain PL, et al. biosynthesis and post-traslational modification ofg CD6, a T cell signal-transducing molecule. J Biol Chem 1991;266(11):7137-43

  20. Aruffo, A, Melnick MB, Linsley PS. The lymphocyte glycoprotein CD6 contains a repeated domain structure characteristic of a new family of cell surface and secreted proteins. J. Exp. Med 1991; 174(4):949-52

  21. Jorgensen C, Couret J, Bologna C, et al. Radiolabelled lymphocite migration in rheumatoid synovitis. Ann Rheum Dis 1995; 54(1): 39-44

  22. Kirkman, RL, Araujo Jl, Busch GJ, Carpe CB, et al. Treament of acute allograft rejection with monoclonal anti-T12 antibodies. Transplantation 1983; 36: 620-626

  23. Osorio, L.M, Garcia CA, Jondal M, Chow SC. The anti CD6 mAb, ior t1, defined a new epitope on the human CD6 molecula that induces greater responsiveness in the cell receptor/CD3-mediated T cell proliferation. Cellular Immunol.1994; 154(1):123-133

  24. García CA, Barral AM, Torres K. El anticuerpo monoclonal ior t1 reconoce un epítope dentro del CD6 antígenos de diferenciación leucocitario humano. Biotecnología Aplicada 1992; (1):70-4

  25. Rodríguez, T, García CA, Vázquez AM, et al. Obtención de hibridomas de ratón productores de anticuerpos monoclonales que reconocen células humanas de origen T. Interferón y Biotecnología 1985; 2(1):41-46

  26. Faxas, ME, Barral AM, Garcia CA. The anti-CD6 monoclonal antibody iot t1 does not inhibit the antigent-specific cellcytotoxicity in vitro. Biotecnol Aplicada 1993; 10(1):47-50.

  27. Clinical Trial Report. Phase I Clinical Trial “Toxicological evaluation of the humanized T1h (anti-CD6) Monoclonal Antibody in patients with Rheumatoid Arthritis“. Center of Molecular Immunology. February 22nd, 2007

  28. Milera Rodríguez. Joel Miguel. Evaluación de la seguridad y eficacia del T1h (Anti-CD6) como monoterapia en pacientes con Artritis Reumatoide.2010 [Tesis de grado]

  29. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid artritis. Arthritis Rheum. 1988; 31:315-324

  30. Scott DL. Prognostic factors in early rheumatoid artritis. Rheumatology 2000; 39(suppl 1): 24-29

  31. Lard L.R., Visser H., Speyer I., Van der Horst-Bruinsma I.E., Zwinderman A.H., Breedveld F.C., et-al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med. 2001; 111:446-51

  32. Nell V.P., Machold K.P., Eberl G., Stamm T.A., Uffmann M., Smolen J.S. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2004; 43:906-14

  33. Vetter G, Geisslinger G, Tegeder I. Release of glutamate, nitric oxide and prostaglandin E2 and metabolic activity in the spinal cord of rats following peripheral nociceptive stimulation. Pain 2001; 92:213-218

  34. Scott D.L., Kingsley G.H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med. 2006; 355:704-12

  35. Sibilia J., Westhovens R. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2007; 25(Suppl 46):S46-56.

  36. Abasolo L., Judez E., Descalzo M.A., Gonzalez-Alvaro I., Jover J.A., Carmona L. Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. Semin Arthritis Rheum. 2008; 37:388-97

  37. Dixon WG, Carmona L, Finckh A, Hetland ML, Kvien TK, Landewe R, et al. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis. 2010; 69: 1596-602

  38. Predictive factors for disability as evaluated by the health assessment questionnaire in rheumatoid arthritis: a literature review. Inflamm Allergy Drug Targets. 2010 Mar ;9(1):51-9. PubMed

  39. Tanaka E, Mannalithara A, Inoue E, Hara M, Tomatsu T, Kamatani N, Singh G, Yamanaka H . Efficient management of rheumatoid arthritis significantly reduces long-term functional disability. . Ann Rheum Dis. 2008 Aug; 67(8):1153-8. Epub 2007 Oct 30.

  40. Jorgensen C, Couret J, Bologna C, et al. Radiolabelled lymphocite migration in rheumatoid synovitis. Ann Rheum Dis 1995; 54(1): 39-44

  41. Cárdenas L, Carreras AC, Yague E, et al. Phosphorylation-dephosphorylation of the CD6 glycoprotein renders two isoforms of 130 and 150 kilodaltons. Effects of serum and protein Kinase C activators. J Immunol 1990, 145:1450-1455

  42. Singer, GN, Richardson BC, Powers D, Hooper F. Role of the CD6 glycoprotein in antigen especific and autoreactive responses of cloned human T lymphocytes. Immunology. Immunology. 1996; 88(4): 537-543

  43. Higgs, JB, Zejdes W, Kozarsky K, Schteingart, et al. A novel pathway of human lymphocyte activation. Identification by a monoclonal antibody generated against a rheumatoid sinovial T cell line. J Immunol 1988;140(11): 3758-3765




2020     |     www.medigraphic.com